Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, DuPont HL.

J Antimicrob Chemother. 2011 Dec;66(12):2850-5. doi: 10.1093/jac/dkr377.

PMID:
21948965
2.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Review.

PMID:
21741091
3.

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.

Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN.

Anaerobe. 2009 Dec;15(6):290-1. doi: 10.1016/j.anaerobe.2009.08.004.

PMID:
19698797
4.

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series.

Neff G, Zacharias V, Kaiser TE, Gaddis A, Kemmer N.

Liver Transpl. 2010 Aug;16(8):960-3. doi: 10.1002/lt.22092.

5.

Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.

Zanger P, Nurjadi D, Gabor J, Gaile M, Kremsner PG.

Lancet Infect Dis. 2013 Nov;13(11):946-54. doi: 10.1016/S1473-3099(13)70221-4.

PMID:
24012319
6.

Rifaximin in the treatment of recurrent Clostridium difficile infection.

Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ.

Aliment Pharmacol Ther. 2013 Jan;37(1):122-8. doi: 10.1111/apt.12111.

7.

Best strategies in recurrent or persistent Clostridium difficile infection.

Cocanour CS.

Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Review.

PMID:
21767157
8.

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.

Garey KW, Jiang ZD, Bellard A, Dupont HL.

J Clin Gastroenterol. 2009 Jan;43(1):91-3. doi: 10.1097/MCG.0b013e31814a4e97. No abstract available.

PMID:
18385603
9.

[Treatment of recurrent Clostridium difficile diarrhoea using sequential therapy with vancomycin followed by rifaximin].

Zelada Rodríguez MA, Rodríguez D, Martí X, Espejo E.

Rev Esp Geriatr Gerontol. 2012 Jan-Feb;47(1):42-4. doi: 10.1016/j.regg.2011.06.010. Spanish. No abstract available.

PMID:
22105006
10.

Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN.

Clin Infect Dis. 2007 Mar 15;44(6):846-8.

PMID:
17304459
11.

Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial.

Selinger CP, Bell A, Cairns A, Lockett M, Sebastian S, Haslam N.

J Hosp Infect. 2013 Jun;84(2):159-65. doi: 10.1016/j.jhin.2013.02.019.

12.

Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.

Rodriguez S, Hernandez MB, Tarchini G, Zaleski M, Vatanchi M, Cardona L, Castro-Pavia F, Schneider A.

Clin Gastroenterol Hepatol. 2014 Nov;12(11):1856-61. doi: 10.1016/j.cgh.2014.02.040.

PMID:
24681079
13.

Clinical predictors of recurrent Clostridium difficile infection in out-patients.

Shivashankar R, Khanna S, Kammer PP, Scott Harmsen W, Zinsmeister AR, Baddour LM, Pardi DS.

Aliment Pharmacol Ther. 2014 Sep;40(5):518-22. doi: 10.1111/apt.12864.

14.

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.

Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S.

JAMA. 2015 May 5;313(17):1719-27. doi: 10.1001/jama.2015.3725.

PMID:
25942722
15.

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.

DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F.

Ann Intern Med. 2005 May 17;142(10):805-12. Erratum in: Ann Intern Med. 2005 Aug 2;143(3):239.

PMID:
15897530
16.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

17.

Oral teicoplanin for successful treatment of severe refractory Clostridium difficile infection.

Popovic N, Korac M, Nesic Z, Milosevic B, Urosevic A, Jevtovic D, Pelemis M, Delic D, Prostran M, Milosevic I.

J Infect Dev Ctries. 2015 Oct 29;9(10):1062-7. doi: 10.3855/jidc.6335.

18.

Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.

El-Herte RI, Baban TA, Kanj SS.

Scand J Infect Dis. 2012 Mar;44(3):228-30. doi: 10.3109/00365548.2011.616224. Review.

PMID:
22077098
19.

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, Rees R, Taylor B, Wood E, Malakun R.

Cochrane Database Syst Rev. 2011 Sep 7;(9):CD004610. doi: 10.1002/14651858.CD004610.pub4. Review.

PMID:
21901692
20.

Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.

Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ.

J Antimicrob Chemother. 2012 Mar;67(3):742-8. doi: 10.1093/jac/dkr508.

PMID:
22146873

Supplemental Content

Support Center